sub:assertion {
d:DB01393 dv:ddi-interactor-in dr:DB01393_DB01432 .
d:DB01432 dv:ddi-interactor-in dr:DB01393_DB01432 .
dr:DB01393_DB01432 dct:identifier "drugbank_resource:DB01393_DB01432" ;
dct:title "DDI between Bezafibrate and Cholestyramine - Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label """DDI between Bezafibrate and Cholestyramine - Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.
[drugbank_resource:DB01393_DB01432]"""@en .
}